Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VTYX |
---|---|---|
09:32 ET | 1883 | 2.19 |
09:34 ET | 7773 | 2.18 |
09:36 ET | 22413 | 2.17 |
09:38 ET | 6950 | 2.175 |
09:39 ET | 1006 | 2.175 |
09:41 ET | 360 | 2.175 |
09:43 ET | 1740 | 2.16 |
09:45 ET | 100 | 2.16 |
09:48 ET | 300 | 2.165 |
09:50 ET | 200 | 2.165 |
09:54 ET | 100 | 2.165 |
09:56 ET | 300 | 2.16 |
09:57 ET | 5121 | 2.18 |
09:59 ET | 5276 | 2.165 |
10:01 ET | 18257 | 2.2 |
10:03 ET | 13029 | 2.21 |
10:06 ET | 34251 | 2.2 |
10:08 ET | 5075 | 2.195 |
10:10 ET | 738 | 2.185 |
10:12 ET | 2210 | 2.185 |
10:14 ET | 755 | 2.185 |
10:15 ET | 413 | 2.18 |
10:17 ET | 3639 | 2.195 |
10:19 ET | 3252 | 2.17 |
10:21 ET | 2142 | 2.16 |
10:24 ET | 8719 | 2.145 |
10:26 ET | 2400 | 2.16 |
10:28 ET | 6580 | 2.1515 |
10:30 ET | 32328 | 2.155 |
10:32 ET | 2814 | 2.15 |
10:33 ET | 1624 | 2.155 |
10:35 ET | 600 | 2.155 |
10:37 ET | 1100 | 2.155 |
10:39 ET | 2451 | 2.165 |
10:42 ET | 10974 | 2.155 |
10:44 ET | 870 | 2.155 |
10:46 ET | 288 | 2.15 |
10:48 ET | 3716 | 2.155 |
10:50 ET | 1374 | 2.1588 |
10:51 ET | 20880 | 2.145 |
10:53 ET | 1138 | 2.135 |
10:55 ET | 500 | 2.135 |
10:57 ET | 779 | 2.132 |
11:00 ET | 1697 | 2.135 |
11:02 ET | 7628 | 2.13 |
11:04 ET | 1400 | 2.1389 |
11:06 ET | 7701 | 2.122 |
11:08 ET | 13713 | 2.127 |
11:09 ET | 8580 | 2.1136 |
11:11 ET | 1503 | 2.115 |
11:13 ET | 1052 | 2.112 |
11:15 ET | 5079 | 2.12 |
11:18 ET | 863 | 2.115 |
11:20 ET | 1930 | 2.115 |
11:22 ET | 1340 | 2.115 |
11:24 ET | 1721 | 2.115 |
11:26 ET | 6085 | 2.12 |
11:27 ET | 6383 | 2.125 |
11:29 ET | 3311 | 2.12 |
11:31 ET | 3800 | 2.125 |
11:33 ET | 1849 | 2.125 |
11:36 ET | 700 | 2.125 |
11:38 ET | 1056 | 2.125 |
11:40 ET | 1800 | 2.125 |
11:42 ET | 600 | 2.12 |
11:44 ET | 6535 | 2.135 |
11:45 ET | 1400 | 2.1389 |
11:47 ET | 1219 | 2.135 |
11:49 ET | 536 | 2.135 |
11:51 ET | 400 | 2.125 |
11:54 ET | 1866 | 2.135 |
11:56 ET | 1199 | 2.12 |
11:58 ET | 2097 | 2.125 |
12:00 ET | 200 | 2.125 |
12:02 ET | 502 | 2.12 |
12:03 ET | 420 | 2.125 |
12:05 ET | 600 | 2.125 |
12:07 ET | 1737 | 2.135 |
12:09 ET | 800 | 2.1301 |
12:12 ET | 230 | 2.13 |
12:16 ET | 700 | 2.135 |
12:18 ET | 100 | 2.13 |
12:20 ET | 2100 | 2.125 |
12:21 ET | 500 | 2.12 |
12:23 ET | 700 | 2.125 |
12:25 ET | 200 | 2.12 |
12:27 ET | 200 | 2.12 |
12:30 ET | 263 | 2.1292 |
12:32 ET | 300 | 2.12 |
12:34 ET | 6072 | 2.125 |
12:36 ET | 6700 | 2.12 |
12:38 ET | 2685 | 2.12 |
12:39 ET | 700 | 2.125 |
12:41 ET | 27726 | 2.115 |
12:43 ET | 1920 | 2.115 |
12:45 ET | 4115 | 2.11 |
12:48 ET | 26298 | 2.105 |
12:50 ET | 600 | 2.105 |
12:52 ET | 986 | 2.105 |
12:54 ET | 6000 | 2.115 |
12:56 ET | 11350 | 2.12 |
12:57 ET | 788 | 2.125 |
12:59 ET | 1190 | 2.125 |
01:01 ET | 3424 | 2.13 |
01:03 ET | 826 | 2.125 |
01:06 ET | 500 | 2.12 |
01:08 ET | 2312 | 2.115 |
01:10 ET | 10743 | 2.1101 |
01:12 ET | 2400 | 2.115 |
01:14 ET | 6947 | 2.1 |
01:15 ET | 25882 | 2.1 |
01:17 ET | 1656 | 2.09 |
01:19 ET | 2000 | 2.095 |
01:21 ET | 1900 | 2.095 |
01:24 ET | 900 | 2.095 |
01:26 ET | 3107 | 2.095 |
01:28 ET | 9848 | 2.1 |
01:30 ET | 7721 | 2.095 |
01:32 ET | 1500 | 2.095 |
01:33 ET | 3134 | 2.0992 |
01:35 ET | 2352 | 2.0993 |
01:37 ET | 572 | 2.095 |
01:39 ET | 600 | 2.095 |
01:42 ET | 500 | 2.095 |
01:44 ET | 816 | 2.09 |
01:46 ET | 2710 | 2.1 |
01:48 ET | 1558 | 2.09 |
01:50 ET | 950 | 2.09 |
01:51 ET | 1206 | 2.09 |
01:53 ET | 1100 | 2.095 |
01:55 ET | 900 | 2.09 |
01:57 ET | 16434 | 2.105 |
02:00 ET | 1300 | 2.105 |
02:02 ET | 3100 | 2.115 |
02:04 ET | 500 | 2.115 |
02:06 ET | 800 | 2.11 |
02:08 ET | 4040 | 2.12 |
02:09 ET | 2271 | 2.1 |
02:11 ET | 1181 | 2.1 |
02:13 ET | 3150 | 2.105 |
02:15 ET | 700 | 2.1092 |
02:18 ET | 6501 | 2.125 |
02:20 ET | 2165 | 2.11 |
02:22 ET | 2700 | 2.105 |
02:24 ET | 900 | 2.105 |
02:26 ET | 500 | 2.105 |
02:27 ET | 4521 | 2.115 |
02:29 ET | 597 | 2.11 |
02:31 ET | 1502 | 2.1108 |
02:33 ET | 2077 | 2.115 |
02:36 ET | 2315 | 2.1 |
02:38 ET | 2623 | 2.1036 |
02:40 ET | 5895 | 2.1 |
02:42 ET | 2400 | 2.095 |
02:44 ET | 4966 | 2.0983 |
02:45 ET | 2922 | 2.105 |
02:47 ET | 1300 | 2.115 |
02:49 ET | 1940 | 2.115 |
02:51 ET | 3382 | 2.105 |
02:54 ET | 1423 | 2.105 |
02:56 ET | 300 | 2.105 |
02:58 ET | 5050 | 2.105 |
03:00 ET | 2850 | 2.118 |
03:02 ET | 14919 | 2.115 |
03:03 ET | 5781 | 2.115 |
03:05 ET | 2065 | 2.11 |
03:07 ET | 1887 | 2.105 |
03:09 ET | 300 | 2.102 |
03:12 ET | 400 | 2.1 |
03:14 ET | 596 | 2.105 |
03:16 ET | 500 | 2.1 |
03:18 ET | 5121 | 2.105 |
03:20 ET | 1487 | 2.1001 |
03:21 ET | 2800 | 2.092 |
03:23 ET | 19282 | 2.105 |
03:25 ET | 700 | 2.1 |
03:27 ET | 1593 | 2.105 |
03:30 ET | 1060 | 2.105 |
03:32 ET | 100 | 2.105 |
03:34 ET | 6251 | 2.095 |
03:36 ET | 1987 | 2.09 |
03:38 ET | 3831 | 2.085 |
03:39 ET | 5586 | 2.095 |
03:41 ET | 702 | 2.095 |
03:43 ET | 400 | 2.095 |
03:45 ET | 7579 | 2.095 |
03:48 ET | 2700 | 2.1 |
03:50 ET | 8872 | 2.105 |
03:52 ET | 3099 | 2.1028 |
03:54 ET | 1908 | 2.105 |
03:56 ET | 19633 | 2.1 |
03:57 ET | 34421 | 2.08 |
03:59 ET | 150883 | 2.08 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Ventyx Biosciences Inc | 154.1M | -0.7x | --- |
Tenaya Therapeutics Inc | 152.3M | -1.2x | --- |
Acumen Pharmaceuticals Inc | 149.0M | -2.2x | --- |
Immunic Inc | 148.6M | -1.1x | --- |
Context Therapeutics Inc | 147.0M | -1.8x | --- |
Actuate Therapeutics Inc | 145.5M | 0.0x | --- |
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company’s pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $154.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.79 |
Book Value | $4.12 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.